Other Events ·
Nasdaq notifies Silexion Therapeutics of non-compliance with $1.00 minimum bid price requirement
SLXNWSilexion Therapeutics Corp
Silexion Therapeutics Corp received a notice from Nasdaq on September 25, 2026, indicating that its ordinary shares failed to maintain the minimum $1.00 per share bid price requirement for 30 consecutive business days. The Nasdaq Listing Qualifications Department notified the company of this deficiency and stated that the Nasdaq Hearings Panel will consider whether to allow Silexion to remain listed on the Nasdaq Capital Market. While the notice has no immediate effect on trading under the symbol SLXN, it signals significant regulatory risk regarding the company's continued listing status. Silexion Therapeutics Corp operates in the biotechnology industry, focusing on the development of therapeutic treatments.